Clinical trial
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine…
NCT00225056 · Oncology Specialties, Alabama, Other · Terminated
Key facts
| NCT number | NCT00225056 |
|---|---|
| Title | Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma |
| Official title | Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma |
| Lead sponsor | Oncology Specialties, Alabama, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel and capecitabine |
| Enrollment | 43 |
| Start date | Oct 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Sep 23, 2005 |
| Last update posted | Apr 20, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: